Spektron Systems is a new type of drug discovery utilizing proprietary machine learning, AI and neural network approaches. The team is comprised of both seasoned pharma experts as well as experts in disciplines not customary of drug discovery. The Company’s Team is uniquely capable of practicing and advancing our proprietary Q-MAP™ drug design platform focused on the development of novel new drugs to address drying drug pipelines. Q-MAP™ enables the development of novel new drugs faster and at lower costs than the leading conventional methods. After completion of the Company’s current three discovery programs, our team will focus on a diversified group of new biological pathways as well as drugs that are needed for the developing/emerging market and for rare diseases. With scientific developments nearly two decades in the making and a talented team from around the world, Spektron is aimed at bringing novel new drugs to market over the next five years.